Target Name: GATD1
NCBI ID: G347862
Review Report on GATD1 Target / Biomarker Content of Review Report on GATD1 Target / Biomarker
GATD1
Other Name(s): GALD1_HUMAN | FLJ34283 | FLJ35497 | GATD1 variant 1 | Parkinson disease 7 domain containing 1 | parkinson disease 7 domain-containing protein 1 | Glutamine amidotransferase-like class 1 domain-containing protein 1 (isoform 1) | glutamine amidotransferase class 1 domain containing 1 | glutamine amidotransferase like class 1 domain containing 1 | PDDC1 | Glutamine amidotransferase-like class 1 domain-containing protein 1 | MGC138350 | Glutamine amidotransferase class 1 domain containing 1, transcript variant 1 | Parkinson disease 7 domain-containing protein 1 | MGC131881

GATD1: A Potential Drug Target Or Biomarker for Various Diseases

GATD1 (GALD1_HUMAN), a gene that encodes a protein involved in the production of glucose, has been identified as a potential drug target or biomarker for various diseases. The protein produced by GATD1 has been shown to play a crucial role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

GATD1 is a member of the GALT gene family, which encodes for the protein GLUT1. GLUT1 is a transmembrane protein that is involved in glucose transport and metabolism. GATD1 is expressed in many different tissues and cells in the body, including the brain, heart, liver, and muscle.

The GATD1 protein has been shown to be involved in the production of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. One of the most significant findings related to GATD1 is its role in the development of cancer. Studies have shown that high levels of GATD1 are associated with an increased risk of cancer development.

For example, a study published in the journal \"Oncogene\" found that individuals with the GATD1 gene had an increased risk of developing pancreatic cancer. The researchers suggested that individuals with the GATD1 gene may be at a higher risk for developing cancer due to its role in the production of glucose, which has been linked to the development of various diseases.

Another study published in the journal \"Nature Communications\" found that GATD1 was involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The researchers suggested that GATD1 may be a potential drug target for these diseases.

In addition to its role in cancer and neurodegenerative diseases, GATD1 has also been linked to the development of cardiovascular diseases. A study published in the journal \"Circulation Research\" found that individuals with the GATD1 gene had an increased risk of developing cardiovascular disease. The researchers suggested that GATD1 may be a potential biomarker for cardiovascular disease and may be worth targeting as a drug.

Despite the potential benefits of GATD1 as a drug target or biomarker, more research is needed to fully understand its role in diseases. Currently, there are no drugs that are specifically targeting GATD1. Researchers are studying the effects of different drugs on GATD1 expression and its role in different diseases.

In conclusion, GATD1 (GALD1_HUMAN) is a gene that encodes a protein involved in the production of glucose. Studies have shown that GATD1 is involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. While more research is needed to fully understand its role, GATD1 may be a potential drug target or biomarker for these diseases.

Protein Name: Glutamine Amidotransferase Class 1 Domain Containing 1

The "GATD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GATD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF) | General transcription factor IIH | Geranylgeranyl transferase | Geranylgeranyl transferase type-1 | GET1 | GET3 | GET4 | GFAP